SeaStar Medical Holding (ICU) Fair Value & Analysis
Healthcare · US · Market cap $12.5M
SeaStar Medical Holding
ICU · US
Fair value as of: Jul 18, 2026
From 1 valuation models · updated today
Share price +30.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.21 – $12.40 · fair‑value band $1.38 – $2.62 · the $4.00 price screens above the $2.09 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SeaStar Medical Holding (ICU) currently trades at $4.00, while our model-based Fair Value estimate is $2.09, implying the stock looks roughly 47.7% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $1.4M. Revenue grew 68.9% year over year. The balance sheet holds a net cash position of $11.5M. Fundamentals as of Jul 18, 2026
Our scenario range runs from $1.38 (bear case) to $2.62 (bull case); at $4.00, the current price sits above that range. The share trades about 68% below its 52-week high and 93% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -17% fair-value upside, at -48%, ICU screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SeaStar Medical Holding reported revenue of $1.2M in FY2025 versus $0 in FY2021. Reported net income was −$12.2M in FY2025.
Is ICU fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $466.79 | $423.67 | -9% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SeaStar Medical Holding (ICU) undervalued?
What is the fair value of ICU?
What is the quality score of ICU?
What is the revenue of SeaStar Medical Holding (ICU)?
What is the net profit margin of ICU?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full SeaStar Medical Holding analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.